Dosage of Lincomycin HCL Astar in details
Lincomycin HCL Astar Dosage
Generic name: Lincomycin HCL Astar HYDROCHLORIDE 300mg in 1mL
Dosage form: injection, solution
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
If significant diarrhea occurs during therapy, this antibacterial should be discontinued.
INTRAMUSCULAR
Adults
Serious infections—600 mg (2 mL) intramuscularly every 24 hours. More severe infections—600 mg (2 mL) intramuscularly every 12 hours or more often.
Pediatric patients over 1 month of age
Serious infections—one intramuscular injection of 10 mg/kg (5 mg/lb) every 24 hours. More severe infections—one intramuscular injection of 10 mg/kg (5 mg/lb) every 12 hours or more often.
INTRAVENOUS
Adults
The intravenous dose will be determined by the severity of the infection. For serious infections doses of 600 mg of Lincomycin HCL Astar (2 mL of Lincomycin HCL Astar) to 1 gram are given every 8 to 12 hours. For more severe infections these doses may have to be increased. In life-threatening situations daily intravenous doses of as much as 8 grams have been given.
Intravenous doses are given on the basis of 1 gram of Lincomycin HCL Astar diluted in not less than 100 mL of appropriate solution and infused over a period of not less than one hour.
| Dose | Vol. Diluent | Time |
|---|---|---|
| 600 mg | 100 mL | 1 hr |
| 1 gram | 100 mL | 1 hr |
| 2 grams | 200 mL | 2 hr |
| 3 grams | 300 mL | 3 hr |
| 4 grams | 400 mL | 4 hr |
These doses may be repeated as often as required to the limit of the maximum recommended daily dose of 8 grams of Lincomycin HCL Astar.
Pediatric patients over 1 month of age
10 to 20 mg/kg/day (5 to 10 mg/lb/day) depending on the severity of the infection may be infused in divided doses as described above for adults.
NOTE: Severe cardiopulmonary reactions have occurred when this drug has been given at greater than the recommended concentration and rate.
SUBCONJUNCTIVAL INJECTION
0.25 mL (75 mg) injected subconjunctivally will result in ocular fluid levels of antibacterial (lasting for at least 5 hours) with MICs sufficient for most susceptible pathogens.
Patients with diminished renal function
When therapy with Lincomycin HCL Astar is required in individuals with severe impairment of renal function, an appropriate dose is 25 to 30% of that recommended for patients with normally functioning kidneys.
More about Lincomycin HCL Astar (Lincomycin HCL Astar)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- En Espanol
- 1 Review - Add your own review/rating
- Generic Availability
Consumer resources
- Lincomycin HCL Astar
- Lincomycin HCL Astar (Advanced Reading)
Professional resources
- Lincomycin HCL Astar (AHFS Monograph)
- Lincomycin HCL Astar (FDA)
Related treatment guides
- Bacterial Infection
- Conjunctivitis, Bacterial
What other drugs will affect Lincomycin HCL Astar?
Before receiving Lincomycin HCL Astar, tell your doctor if you are also using erythromycin (E-Mycin, E.E.S., Ery-Tab, Erythrocin, and others).
There may be other drugs that can interact with Lincomycin HCL Astar. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.
Lincomycin HCL Astar interactions
BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Avoid combination
BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Monitor therapy
Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Avoid combination
Doxofylline: Lincomycin HCL Astar may increase the serum concentration of Doxofylline. Monitor therapy
Erythromycin (Systemic): May diminish the therapeutic effect of Lincomycin HCL Astar. Avoid combination
Kaolin: May decrease the absorption of Lincosamide Antibiotics. Monitor therapy
Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Monitor therapy
Mecamylamine: Lincosamide Antibiotics may enhance the neuromuscular-blocking effect of Mecamylamine. Avoid combination
Neuromuscular-Blocking Agents: Lincosamide Antibiotics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Monitor therapy
Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Consider therapy modification
Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents. Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents. Consider therapy modification
References
- FDA/SPL Indexing Data. "BOD072YW0F: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
- MeSH. "Protein Synthesis Inhibitors". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
- European Chemicals Agency - ECHA. "lincomycin: The European Chemicals Agency (ECHA) is an agency of the European Union which is the driving force among regulatory authorities in implementing the EU's groundbreaking chemicals legislation for the benefit of human health and the environment as well as for innovation and competitiveness.". https://echa.europa.eu/ (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Lincomycin HCL Astar are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Lincomycin HCL Astar. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported frequency of use
No survey data has been collected yetConsumer reported doses
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
